Sub: Drug Utilization pattern to assess the real-life usage of topical and systemic antifungal drugs along with Co-Rx of anti-histamines in treatment of fungal infection.

Tinea infections are superficial fungal infections caused by dermatophytes which affect millions of people throughout the world, causing immense distress to the patients. Treatment requires attention to exacerbating factors such as skin moisture and choosing an appropriate antifungal agent.

Management of dermatophytosis include use of antifungals (topical and systemic). At times antihistamines are prescribed to treat the itch associated with dermatophytosis.

Although every product is marketed only after regulatory approval, it is important to know how it performs in day-to-day practice of individual medical practitioners. For this purpose, we have planed to conduct a drug utilization pattern to assess the real-life usage of topical and systemic antifungal drugs along with Co-Rx of anti-histamines in treatment of fungal infection.

We invite you to participate in this drug utilization pattern study. All you need to do is to report on a standard form your experience of management of dermatophytosis.

If you agree to participate, you will need to provide assessment response, on to the standard data collection form (which we call DCF). A monitor will assist you in verifying and collecting the DCF.

We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.